Exicure Inc. (XCUR) Names James Sulat to Board

Exicure, Inc. (NASDAQ: XCUR) today announced the appointment of James Sulat to its Board of Directors.

James “Jim” Sulat joins Exicure after decades of experience advising and leading biopharmaceutical companies, including serving in the roles of President, Chief Executive Officer and Chief Financial Officer at various companies. Mr. Sulat currently serves on the boards of directors of Valneva SE and Arch Therapeutics and previously served on the boards of directors of other companies including AMAG Pharmaceuticals, Momenta Pharmaceuticals and Tolero Pharmaceuticals. Mr. Sulat served in several roles at Memory Pharmaceuticals from 2005 to 2009, a biopharmaceutical company focused on developing innovative drugs for the treatment of debilitating CNS disorders, which was acquired by Roche. Mr. Sulat holds a Bachelor of Science in Administrative Sciences from Yale University and a Master of Business Administration and a Master of Science in Health Services Administration from Stanford University.

“We are pleased to welcome Jim to our board. His extensive biopharmaceutical experience in business development, finance and building companies will be an asset to our Board and beneficial to Exicure’s future growth," said Timothy P. Walbert, Chairman of Exicure’s Board of Directors.

Exicure also announced today that Jay Venkatesan has stepped down from the Board of Directors, effective December 29, 2020.

“We would like to thank Jay for his tremendous support and guidance during the early formation and growth of Exicure,” said Dr. Giljohann, Exicure’s Chief Executive Officer.

You May Also Be Interested In

• Polar Power adds two directors with defense and business experience
• Interstate Power and Light prices $500 million in senior debentures
• Tonix Pharma CEO named interim chief medical officer